Bio-Rad Q3 Revenues Grow 5 Percent

Nov 02, 2017

|

This article has been updated from a previous version to include comments from Bio-Rad's earnings call.

NEW YORK (GenomeWeb) – Bio-Rad said after the close of the market Thursday that its third quarter revenues increased 5 percent year over year.

For the three months ended Sept. 30, the Hercules, California-based life science research and clinical diagnostics firm tallied sales of $535.0 million compared to $508.7 million in the year-ago period, beating analysts' average estimate of $508 million. On a currency-neutral basis, net sales grew 3 percent in the quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Same Scam, New Tech

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

Gene Therapy for SCID-X1

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

To Guide the Genealogy Search

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

This Week in Nature

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.

Featured White Papers

Epigenomic Analysis of Sorted Retinal Ganglion Cells using ATAC-seq

Cloning Bovine Immunoglobulin VH and VL Genes from Single B Cells

Automated RT qPCR Utilizing the Access Workstation, the Echo Liquid Handler, and RealTime Ready Reagents from Roche Applied Science

High-throughput Miniaturized Quantitative PCR with the Echo 525 Liquid Handler

May

08

Featured Webinar

OncoBEAM ctDNA Testing for Early Response Prediction and Therapy Surveillance in Melanoma and Pancreatic Cancer

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May

22

Featured Webinar

A Digital PCR Liquid Biopsy Workflow for Mutation Detection and Therapeutic Monitoring

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.

Menu